Cargando…
Advances and controversies in the management of early stage non-small cell lung cancer
Complete resection continues to be the gold standard for the treatment of early-stage lung cancer. The landmark Lung Cancer Study Group trial in 1995 established lobectomy as the minimum intervention necessary for the management of early-stage non-small cell lung cancer, as it was associated with lo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716990/ https://www.ncbi.nlm.nih.gov/pubmed/35070733 http://dx.doi.org/10.5306/wjco.v12.i12.1089 |
_version_ | 1784624439757897728 |
---|---|
author | Cilleruelo-Ramos, Angel Cladellas-Gutiérrez, Esther de la Pinta, Carolina Quintana-Cortés, Laura Sosa-Fajardo, Paloma Couñago, Felipe Mielgo-Rubio, Xabier Trujillo-Reyes, Juan Carlos |
author_facet | Cilleruelo-Ramos, Angel Cladellas-Gutiérrez, Esther de la Pinta, Carolina Quintana-Cortés, Laura Sosa-Fajardo, Paloma Couñago, Felipe Mielgo-Rubio, Xabier Trujillo-Reyes, Juan Carlos |
author_sort | Cilleruelo-Ramos, Angel |
collection | PubMed |
description | Complete resection continues to be the gold standard for the treatment of early-stage lung cancer. The landmark Lung Cancer Study Group trial in 1995 established lobectomy as the minimum intervention necessary for the management of early-stage non-small cell lung cancer, as it was associated with lower recurrence and metastasis rates than sublobar resection and lower postoperative morbidity and mortality than pneumonectomy. There is a growing tendency to perform sublobar resection in selected cases, as, depending on factors such as tumor size, histologic subtype, lymph node involvement, and resection margins, it can produce similar oncological results to lobectomy. Alternative treatments such as stereotactic body radiotherapy and radiofrequency ablation can also produce good outcomes in inoperable patients or patients who refuse surgery. |
format | Online Article Text |
id | pubmed-8716990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-87169902022-01-20 Advances and controversies in the management of early stage non-small cell lung cancer Cilleruelo-Ramos, Angel Cladellas-Gutiérrez, Esther de la Pinta, Carolina Quintana-Cortés, Laura Sosa-Fajardo, Paloma Couñago, Felipe Mielgo-Rubio, Xabier Trujillo-Reyes, Juan Carlos World J Clin Oncol Opinion Review Complete resection continues to be the gold standard for the treatment of early-stage lung cancer. The landmark Lung Cancer Study Group trial in 1995 established lobectomy as the minimum intervention necessary for the management of early-stage non-small cell lung cancer, as it was associated with lower recurrence and metastasis rates than sublobar resection and lower postoperative morbidity and mortality than pneumonectomy. There is a growing tendency to perform sublobar resection in selected cases, as, depending on factors such as tumor size, histologic subtype, lymph node involvement, and resection margins, it can produce similar oncological results to lobectomy. Alternative treatments such as stereotactic body radiotherapy and radiofrequency ablation can also produce good outcomes in inoperable patients or patients who refuse surgery. Baishideng Publishing Group Inc 2021-12-24 2021-12-24 /pmc/articles/PMC8716990/ /pubmed/35070733 http://dx.doi.org/10.5306/wjco.v12.i12.1089 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Opinion Review Cilleruelo-Ramos, Angel Cladellas-Gutiérrez, Esther de la Pinta, Carolina Quintana-Cortés, Laura Sosa-Fajardo, Paloma Couñago, Felipe Mielgo-Rubio, Xabier Trujillo-Reyes, Juan Carlos Advances and controversies in the management of early stage non-small cell lung cancer |
title | Advances and controversies in the management of early stage non-small cell lung cancer |
title_full | Advances and controversies in the management of early stage non-small cell lung cancer |
title_fullStr | Advances and controversies in the management of early stage non-small cell lung cancer |
title_full_unstemmed | Advances and controversies in the management of early stage non-small cell lung cancer |
title_short | Advances and controversies in the management of early stage non-small cell lung cancer |
title_sort | advances and controversies in the management of early stage non-small cell lung cancer |
topic | Opinion Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716990/ https://www.ncbi.nlm.nih.gov/pubmed/35070733 http://dx.doi.org/10.5306/wjco.v12.i12.1089 |
work_keys_str_mv | AT cillerueloramosangel advancesandcontroversiesinthemanagementofearlystagenonsmallcelllungcancer AT cladellasgutierrezesther advancesandcontroversiesinthemanagementofearlystagenonsmallcelllungcancer AT delapintacarolina advancesandcontroversiesinthemanagementofearlystagenonsmallcelllungcancer AT quintanacorteslaura advancesandcontroversiesinthemanagementofearlystagenonsmallcelllungcancer AT sosafajardopaloma advancesandcontroversiesinthemanagementofearlystagenonsmallcelllungcancer AT counagofelipe advancesandcontroversiesinthemanagementofearlystagenonsmallcelllungcancer AT mielgorubioxabier advancesandcontroversiesinthemanagementofearlystagenonsmallcelllungcancer AT trujilloreyesjuancarlos advancesandcontroversiesinthemanagementofearlystagenonsmallcelllungcancer |